Welcome to OPT Congress:
Oligonucleotides & mRNA Therapeutics

OPT Congress is the premier conference for scientists and clinicians involved in discovering and developing oligonucleotides as therapeutics. For 2025 we are delighted to expand our content and offer a new conference program dedicated to emerging oligo modalities to showcase where the science is heading in the very near future and share cutting-edge research and technologies with community. Now in its 10th year, this unique event brings together leading chemists, biologists, toxicologists, CMC experts, regulatory specialists and technology providers to discuss advances in next-generation oligonucleotides and mRNA therapeutics. In addition to 2 days of inspiring keynotes, interactive discussions and more than 95 scientific presentations, we deliver in-depth short courses to further add to the learning opportunities while you are on site with us. We look forward to having you join us for this important scientific and networking event, that offers robust and customizable programming.

4 Conferences
95+ Speakers
300+ Attendees
150+ Unique Organizations
2 Pre Conference Short Courses

2024 Plenary Speakers

Jeffery M. Coller

Jeffery M. Coller, PhD
Bloomberg Distinguished Professor of RNA Biology and Therapeutics, Johns Hopkins University

Arthur Krieg, MD

Arthur Krieg, MD
Adjunct Professor, University of Massachusetts, Chan School of Medicine

Mano Manoharan, PhD

Mano Manoharan, PhD
Distinguished Scientist & Senior Vice President, Innovation Chemistry, Alnylam Pharmaceuticals

Laura Sepp-Lorenzino

Laura Sepp-Lorenzino, PhD
CSO, Intellia Therapeutics

Our Executive Advisory Board

Mano Manoharan, PhD
Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals

Dmitry Samarsky, PhD
Former CTO, Sirnaomics

Chandra Vargeese, PhD
CTO & Head, Platform Discovery Sciences, Wave Life Sciences

Arthur Levin, PhD
Executive Vice President, Research and Development, Avidity Biosciences

Lubo Nechev, PhD
Vice President Process and Analytical Sciences, Alnylam Pharmaceuticals

Ekkehard Leberer, PhD
Senior Life Sciences Consultant, ELBIOCON